Abstract Search

ey0019.12-13 | Hyperlipidemia | ESPEYB19

12.13. Vaccine targeting ANGPTL3 ameliorates dyslipidemia and associated diseases in mouse models of obese dyslipidemia and familial hypercholesterolemia

Y Fukami H, Morinaga J, Nakagami H, Hayashi H, Okadome Y, Matsunaga E, Kadomatsu T, Horiguchi H, Sato M, Sugizaki T, Kuwabara T, Miyata K, Mukoyama M, Morishita R, Oike

Reports Medicine 2021;2(11):100446. doi: 10.1016/j.xcrm.2021.100446Brief Summary: This mouse study validated a novel, safe treatment with ANGPTL3 peptide vaccine. It was effective to improve obesity-induced dyslipidemia and fatty liver in mice, and also improved dyslipidemia and atherosclerosis in a mouse model of familial hypercholesterolemia, with no reported toxicity.<p class="abste...

0 shares

ey0017.4-3 | Important for clinical practice | ESPEYB17

4.3. IGF2 Mutations

Y Masunaga , T Inoue , K Yamoto , Y Fujisawa , Y Sato , Y Kawashima-Sonoyama , N Morisada , K Iijima , Y Ohata , N Namba , H Suzumura , R Kuribayashi , Y Yamaguchi , H Yoshihashi , M Fukami , H Saitsu , M Kagami , T Ogata

To read the full abstract: J Clin Endocrinol Metab. 2020 Jan 1;105(1):dgz034.Using different genetic approaches, the authors identified 5 novel pathogenic or likely pathogenic IGF2 gene variants in Japanese patients who underwent genetic testing for the variable associations of multiple congenital anomalies such as mental retardation, Silver-Russell syndrome (SRS), disorders of sex development (DSD), ectrodactyly (split hand/foot malfor...

0 shares

ESPE Yearbook of Paediatric Endocrinology

12.13. Vaccine targeting ANGPTL3 ameliorates dyslipidemia and associated diseases in mouse models of obese dyslipidemia and familial hypercholesterolemia

4.3. IGF2 Mutations

BiosciAbstracts